Executive Spotlights

Poseida inks deal with Roche for $110M initially and potentially $6B in aggregate value.

San Diego, CA, August, 3, 2022 (street insider) — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced it has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel “off-the-shelf” cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications.

Poseida Therapeutics announces strategic global collaboration with Roche focused on #allogeneic CAR-T cell therapies.

“We are excited to partner and collaborate with Roche, one of the world’s largest biotechnology companies, which has a successful track record in the discovery, development and commercialization of innovative medicines,” said Mark Gergen, Chief Executive Officer of Poseida. “Roche is an ideal strategic partner for Poseida with its industry-leading R&D capabilities in oncology, complementary technologies and expertise, and global regulatory and commercial capabilities. Working together, we look forward to advancing novel allogeneic cell therapies based upon Poseida’s technologies for patients battling cancer.”


Source: https://www.streetinsider.com/Corporate+News/Poseida+Therapeutics+%28PSTX%29+Announces+Pact+with+Roche+Focused+on+Allogeneic+CAR-T+Cell+Therapies+for+Hematologic+Malignancies/20407329.html



Life Science Headlines